Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fidelity Investments, otherwise known as FMR LLC has also been quietly selling off MBLX.
Heavy Selling
I don't think anybody trusts The Bollinger report aka GainHunter.com.
They both share the same Denver, Colorado-based ISP of 72.18.133.75 They did the same to BGMD which is also tanking and will be in panic mode, soon.
Heavy Selling
I don't think anybody trusts The Bollinger report aka GainHunter.com.
They both share the same Denver, Colorado-based ISP of 72.18.133.75 They did the same to MBLX which is also tanking and will be in panic mode, soon.
There sure is a lot of pumping going on in here, think I'll pass.
Good luck longs, lol
All the biotechs lose money for the longest time, until one day they produce something big .... I also think the stock will pass the $1 mark before mid September. I really don't care what the shorts believe, or what or how old the information is that they continuously re-post. I do think liquidity is going to be a problem when they try to escape their fungled short positions. <(-'.'-)>
March 3, 2010 (FinancialWire) (Investrend Broadcast Syndicate) -- Information for conference calls listed here can be accessed via the Conference Call Search Function at BestCalls (http://www.bestcalls.com) by referencing the company ticker symbol. Conference calls scheduled today at 2 to 2:05 p.m. include: Yahoo! Inc. (NASDAQ: YHOO), XOMA Limited (NASDAQ: XOMA), ImmunoGen Inc. (NASDAQ: IMGN).
Hey Ferry, you short too?
It looks like we've got a correction in progress, fellas. This little biotech stock wants to run. You know the stock has been heavily shorted when the stock bashers are hard at work digging up dirt from 3yrs ago and posting it on investorshub. The money will come in from the other biotechs like CTIC that shot-up and now are falling back due to their own FDA failures. XOMA hasn't made it's run yet and the past failures are already priced in. Get ready for either a multi-month run or a fat buyout by big Pharma. This will be XOMA's year.
XOMA Live Webcast 9:00am Feb 9th @ ceo.bio.org
XOMA's technologies enable them to co-formulate and deliver multiple antibodies in a single injectable solution. This facilitates delivery and has the potential to increase efficacy for infectious and other diseases. XOMA 3AB consists of three human antibodies that bind to unique epitopes on the botulinum A toxin, which in composite provide unprecedented potency against the toxin.
They designed XOMA 3AB to neutralize botulinum neurotoxin Type A, which causes paralysis and is a bioterror threat. The presentation of the results was at the 20th Annual International Conference on Antibody Engineering held December 6 to 10 in San Diego, California.
This stock is set to explode on Bioterror threat/hype. It's been irrationally oversold.
Strangely, no BIO Asia announcement for Jan 25th? What is Engle waiting for? I'm not selling and there is no way I would consider selling on a Friday.
I'm still waiting on the reply from Adam Feuerstein <adam.feuerstein@thestreet.com> regarding the recent Canaccord Adams Diabetes & Obesity Conference http://www.metacafe.com/watch/4020116/xoma_ltd_ceo_presents_canaccord_adams_diabetes_obesity_conference .. since he couldn't attend it. I think he might interview Engle again, as a follow-up. I've been waiting for him to either reply or print an article all day, especially with it being Friday and all. It's such a bad day for the market and XOMA lost a whole penny. It would actually be better if his response came out on an up day, but so it goes. Anyway, anyone can write to him, if there is a biotech article which might interest them. Always remember, never sell to shorts on friday afternoon with pending news.
Which is the largest of the investor conferences?
28th Annual J.P. Morgan Healthcare Conference
http://www.jpmorgan.com/pages/jpmorgan/investbk/global/na/usconferences/hc
January 11-14, 2010
San Francisco, CA
7th Annual BIO Asia Partnering Conference
http://bioasia.bio.org/opencms/bioasia/2010/
January 25-26, 2010
Tokyo, Japan
12th Annual BIO CEO & Investor Conference
http://www.ceo.bio.org/opencms/ceo/2010/
February 8-9, 2010
New York, NY
9th Annual Windhover & Windhover PSO
http://www.biowindhover.com/content/Main.aspx
February 23-25, 2010
New York City, NY
BIO-Europe Spring
http://www.ebdgroup.com/bes/
March 8-10, 2010
Barcelona, Spain
BIO Intellectual Property Counsels Spring Conference and Committee Meeting
April 19-21, 2010
New Orleans, LA
BIO International Convention
http://convention.bio.org/
May 3-6, 2010
Chicago, IL
McCormick Place Convention Center
2010 BIO Human Resources Conference
May 4-7, 2010
Chicago, IL
Lobbyist(s): Pat Scannon
Agency: U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Defense - Dept of (DOD)
Date Issue(s) Client Income Expenses
2009-03-31 Defense XOMA (US) LLC 0 130,000
2009-06-30 Defense XOMA (US) LLC 0 120,000
2009-09-30 Defense, Medical / Disease Research / Clinical Labs XOMA (US) LLC 0 90,000
ISSUES RELATING TO BIODEFENSE AND NATIONAL SECURITY, SPECIFICALLY FULL FUNDING FOR MEDICAL COUNTERMEASURE DEVELOPMENT VIA THE BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA). ISSUES REGARDING CRITICAL GOVERNMENT NEEDS FOR FLEXIBLE BIOPHARMACEUTICAL MANUFACTURING AND ADVANCED DEVELOPMENT OF MEDICAL COUNTERMEASURES AGAINST CHEMICAL, BIOLOGICAL, NUCLEAR AND RADIOLOGICAL, AND EMERGING DISEASE THREATS. ISSUES RELATING TO BIOTECH JOB CREATION AND BARDA PROGRAMS.
H.R. 1 / S. 336 "AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009," ALL PROVISIONS RELATING TO BARDA FUNDING. H.R. 1105 "OMNIBUS APPROPRIATIONS ACT, 2009," ALL PROVISIONS RELATING TO BARDA FUNDING VIA THE PUBLIC HEALTH AND SOCIAL SERVICES EMERGENCY FUND OF HHS. ISSUES REGARDING HOMELAND SECURITY PRESIDENTIAL DIRECTIVE 1, SPECIFICALLY PERTAINING TO WHITE HOUSE BIODEFENSE ORGANIZATIONAL STRUCTURE AND TO CHANGES WITHIN THE OFFICE OF THE ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE. ISSUES RELATING TO BIOTERRORISM STORIES IN THE NEWS AND TO PANDEMIC INFLUENZA AND BARDA PROGRAM DETAILS. ISSUES RELATING TO BARDA FY09 PRIORITIES OVERALL.
J.P. Morgan Healthcare Conference January 11 - 14, San Francisco, CA The promise of a Big Pharma partnership for its diabetes drug XOMA 052 will probably bring in new investors leading into the conference. http://www.jpmorgan.com/pages/jpmorgan/investbk/global/na/usconferences/hc
The 7th Annual BIO Asia Partnering Conference is coming up in Tokyo and Tomoyuki Fujisawa of Takeda Pharmaceutical is actually on the Advisory Committee. Fujisawa has quite a high regard for XOMA, since his experience before his last promotion.
The royalties from the recent FDA approval of CIMZIA http://www.ucb.com for moderate to severe rheumatoid arthritis (RA) in adults will be substantial, considering the aging population and projections that the rheumatoid arthritis market is expected to more than double in value to $27 Billion by 2015.
XOMA has a supply agreement with AVEO and is eligible for development milestones and royalty payments on sales of AV-299.
http://investors.xoma.com/releasedetail.cfm?ReleaseID=212457
Super Low Volume, glad I didn't get sucked into the fake HEB squeeze.
Why did they sell 25,000,000 of our common shares for $0.76 when the current price was $0.86 per share? The shares should have been sold at a premium and the stockholders should have benefited. I think this is what all the hubbub is about. Nasdaq called them out on their BS hijaak financing. I don't know how they can fix this except to cancel 25,000,000 outstanding shares or require an extra .10 /share from Wm Smith & Co. Engel needs a new job, he's done enough damage here.
Novo Nordisk CEO called out by Mike Huckman on CNBC Nov 13th and answers the question. Won't you get trumped by formulations of diabetes drugs that have longer actions than daily? http://www.tubechop.com/watch/36898
It's the Chief Financial Officer who will be giving the presentation @ Lazard Healthcare. In case you didn't catch it, Fred Kurland was hired in January, replacing David Boyle and finally gets his day in the sun. "Fred is a seasoned financial executive with over 30 years of experience in biotechnology and pharmaceutical companies including Aviron/MedImmune, Protein Design Labs and Syntex/Roche," noted Steve Engle, Chairman and CEO of XOMA. "He will be a very valuable addition to XOMA's executive team, particularly as our anti-IL-1 beta blocker XOMA 052 advances into Phase 2 trials."
http://investors.xoma.com/releasedetail.cfm?ReleaseID=357473
Good Luck to ALLLLLl !!!!!!!!!!!!!!
Top 10 Projects to Watch: Most Licensable Products
Top 10 Sessions - Cardiovascular/Metabolic
http://www.tapartnerships.com
Wednesday, November 18, 2009
Xoma Ltd. 1:15pm
XOMA-052 for Diabetes and Cardiovascular Disease
A single dose of the experimental injectable drug antibody, known
as XOMA 052 has been shown to improve blood sugar control in
patients with type 2 diabetes. This would be a disease-modifying
drug that allows the pancreas to get back to a more normal state.
A subcutaneous injection that could potentially be given as
infrequently as once a month.
It is designed to block an inflammation-causing protein known as
interleukin-1 beta, which has recently been linked to inflammatory
damage to insulin-producing cells known as islet cells. A single
injection of the antibody reduced levels of HbA1c -- a standard
measure of glucose control -- in four of five tested dose levels
compared to placebo. Median HbA1c levels were reduced in all 5
groups and the reduction was as much as 0.6 percent after 28 days
compared to baseline. With one dose we have a 0.6 percent
improvement. If you extrapolate to three months, the improvement
is probably going to be even better.
The results of the trials, which were presented in Rome at a
meeting of the European Association for the Study of Diabetes,
showed no evidence of serious adverse side effects or infusion
reactions. Dr. Marc Donath, Professor of Endocrinology and
Diabetes at the University Hospital of Zurich, a pioneer in anti-
inflammatory approaches to diabetes treatment, will serve as lead
investigator of Xoma's European trial.
Wednesday November 4, 2009
XOMA Ltd Granted First European Patent Covering XOMA 052
Jeffrey Feldstein just presented in Montreal on October 20th: Abstract D-0856.
Held in cooperation with the Canadian diabetes Association and Diabte Qubec, the 20th World diabetes Congress in Montreal will be one of the world's largest medical conferences a mega-event that is expected to attract over 15,000 delegates to the city from October 18 to 22, 2009. Key opinion leaders from the global diabetes community from over 160 countries - will converge on montreal to discuss the burning issues in diabetes.
$XOMA: Presenting at the Elsevier Business Intelligence and Windhover Conference, upcoming Therapeutic Area Partnerships event beginning Tues November 17-19th in Boston, MA http://bit.ly/1E5HkC This will be following the previous weekend's World Diabetes Day Event on November 14th 2009 http://bit.ly/GuzzD and the 7th World Congress on Insulin Resistance at the Grand Hyatt Hotel, Union Square, San Francisco on 05-07th November 2009 http://bit.ly/Q9qjV. With the new marketing partner to be announced any day now and so many television commercials about saving money on your diabetes medications and such, I expect to see a big upward move in XOMA's PPS in the near-term and more than likely a "short squeeze" to also take place, with the share price being exacerbated.
$XOMA 7th World Congress on Insulin Resistance
Grand Hyatt Hotel, Union Square, San Francisco
05 November 2009 - 07 November 2009
http://www.insulinresistance.us
Form S-3 filings are covering resales of shares by selling shareholders. These are big negatives, since they indicate the volume is being drummed up to absorb the selloffs. Get into one of these with care. If you're really thorough, look at the most recent prospectus or 10-K/KSB to see how many of the restricted shares are eligible for resale. - no thanks!
Does anyone have a list of links for custom scans, so I can make some bookmarks? I was going to use http://bit.ly to shorten the complicated url's. I'm not very good at choosing the criteria, unfortunately. Pinksheets, too .. if possible.
SPNG & SPNGE have apparently been pulled from AOL Finance, even the news and press releases are gone. :(
We are bouncing off .80 with most of the near term resistance at .90. Not bad, though. We could break to .86 or .90 on average volume.
resist. 1.22 2 confirmed
resist. 1.03 3 confirmed
resist. 1.00 4 confirmed
resist. 0.90 12 confirmed
resist. 0.86 5 confirmed
resist. 0.82 11 confirmed
SpongeTech gave away hundreds of thousands of sponges for free since 2007, trying to promote themselves. Just google "spongetech free sponges". Are these being counted in the sales numbers? How much has this cost the company? That's a lot of lost sales at $9.99 ea. I don't know anyone who would actually pay 10 bucks for a car sponge, unless they were trying to promote their investment on youtube. Even then, never saw anyone holding more than one, lol. I also never saw anyone washing themselves with a sponge in the bathtub, unless it was a loofah sponge. How can you scrub clean with a squishy sponge?
Why have the commercials disappeared?
XOMA develops products with Novartis AG, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited, having won a $16 Million BioDefense Contract in June 2008.
I am playing XOMA today, lot of big news on this Biotech.
MAKAMAI, I appreciate your technical analysis. Contrary to what I've been receiving by the marketers, I tend to agree with you. Now I have to search some of your older posts, since you seem to be one of the few honest people on investors hub that I have found. I hope I am not wrong about you. Thank you.
This acquisition, when it closes, sometime prior to July 31, 2009.
... need I say more?
Didn't happen, food for the lobsters, gonna tank.
They have been targeting Indian reservation contracts, maybe that has something to do with it? Upgrade them to 4G for their internet broadband.